Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Jul 3 AMGN S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
Jul 3 SNY Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit
Jul 3 AMGN Health Care Stocks With A Long History Of Dividend Growth And Solid Yields
Jul 3 SNY Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Jul 3 SNY Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Jul 3 SNY Sanofi, Regeneron win EU label expansion for Dupixent in COPD
Jul 3 SNY EMA approves Sanofi’s Dupixent for COPD treatment in adults
Jul 3 SNY Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 3 SNY Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Jul 2 INO INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
Jul 2 MYGN Myriad Genetics Earns 2024 Great Place To Work® Certification™
Jul 2 SNY Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 2 AMGN Dow Jones Falls Amid Powell Speech; Tesla Stock Surges On Deliveries
Jul 1 SNY Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Jul 1 SNY Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
Jul 1 INO Inovio Pharmaceuticals added to Russell 2000 index effective July 1
Jul 1 INO INOVIO Added to Russell 2000® Index Effective July 1, 2024
Jul 1 SNY Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
Jul 1 SNY Sanofi reports findings from Phase II relapsing MS treatment trial
Jul 1 AMGN Dow Jones Rallies After Economic Data; Nvidia Gets Price Target Hike
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags